Sugi Predict

Sugi Predict / Targets / CBX7

CBX7

Chromobox protein homolog 7 · O95931 · CBX7 on Sugi Atlas →

5,379 patent compounds predicted against CBX7, 2,786 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL4413088 SCHEMBL4413088 0.56 9/20
SCHEMBL2950965 SCHEMBL2950965 0.70 8/20
SCHEMBL4246933 SCHEMBL4246933 0.52 7/20
SCHEMBL2953262 SCHEMBL2953262 0.50 7/20
SCHEMBL4692628 SCHEMBL4692628 0.42 7/20
SCHEMBL4242148 SCHEMBL4242148 0.56 6/20
SCHEMBL5544872 SCHEMBL5544872 0.48 6/20
SCHEMBL4692627 SCHEMBL4692627 0.44 6/20
SCHEMBL5546434 SCHEMBL5546434 0.43 6/20
SCHEMBL4416757 SCHEMBL4416757 0.43 6/20
SCHEMBL3706421 SCHEMBL3706421 0.50 5/20
SCHEMBL4413144 SCHEMBL4413144 0.49 5/20
SCHEMBL4944007 SCHEMBL4944007 0.47 5/20
SCHEMBL5535135 SCHEMBL5535135 0.36 5/20
SCHEMBL2829735 SCHEMBL2829735 0.80 4/20
SCHEMBL4414345 SCHEMBL4414345 0.58 4/20
SCHEMBL3026762 SCHEMBL3026762 0.55 4/20
SCHEMBL5283365 SCHEMBL5283365 0.54 4/20
SCHEMBL5754359 SCHEMBL5754359 0.54 4/20
SCHEMBL2953037 SCHEMBL2953037 0.50 4/20

Clinical trials — most relevant to CBX7 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure PHASE2COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer PHASE1/PHASE2SUSPENDED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer PHASE1/PHASE2WITHDRAWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) PHASE2RECRUITING
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer PHASE2UNKNOWN
A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) PHASE1RECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
The Danish TURNER Cryopreservation Study nanRECRUITING
Immunophenotyping and Xist Gene in AML nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants nanRECRUITING
Cause of Familial Testicular Cancer nanCOMPLETED
Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility Genes nanACTIVE_NOT_RECRUITING
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells. nanUNKNOWN
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies nanWITHDRAWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Characterization of At-risk Population for Pre-sacral Tumor in CURRARINO Syndrome nanCOMPLETED
Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System nanUNKNOWN
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia nanCOMPLETED
Target of Suv420h1/2 in Hepatocytes nanRECRUITING
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients nanRECRUITING
Chordoma Family Study nanCOMPLETED
Study of the Sex Differences in Inflammatory Diseases in Children nanUNKNOWN
Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes nanCOMPLETED
X-chromosome Inactivation, Epigenetics and the Transcriptome nanCOMPLETED
Genetic Study of Familial Epilepsy nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CBX7 binder may also engage these)

ProteinNameSimilarity
Q9BUA3 — 0.985 Q9BUA3 →
Q9Y4B5 — 0.984 Q9Y4B5 →
Q9DBY5 — 0.983 Q9DBY5 →
Q8TBE0 — 0.983 Q8TBE0 →
Q497V6 — 0.983 Q497V6 →
A2A9F4 — 0.982 A2A9F4 →
Q3KP66 — 0.982 Q3KP66 →
MSL1 Male-specific lethal 1 homolog 0.982 landscape →
P48382 — 0.982 P48382 →
Q96RK0 — 0.982 Q96RK0 →
Q8BZW2 — 0.982 Q8BZW2 →
Q6PIV2 — 0.982 Q6PIV2 →
Q4R2Z8 — 0.982 Q4R2Z8 →
Q9Z0E3 — 0.982 Q9Z0E3 →
CBX6 Chromobox protein homolog 6 0.981 landscape →
Q6PDM1 — 0.981 Q6PDM1 →
Q86YN6 — 0.981 Q86YN6 →
Q8VDG6 — 0.981 Q8VDG6 →
Q60700 — 0.981 Q60700 →
Q05AH6 — 0.981 Q05AH6 →
Q7TN12 — 0.981 Q7TN12 →
Q5VZ18 — 0.981 Q5VZ18 →
Q9W6D8 — 0.981 Q9W6D8 →
CBX4 E3 SUMO-protein ligase CBX4 0.981 landscape →
Q76N89 — 0.981 Q76N89 →
Q61501 — 0.981 Q61501 →
Q62407 — 0.981 Q62407 →
A0A8I3PMN2 — 0.981 A0A8I3PMN2 →
Q9QXV1 — 0.981 Q9QXV1 →
Q9JL04 — 0.980 Q9JL04 →